Glooko has received U.S. FDA 510(k) clearance for EndoTool IV Cloud, making it the first cloud-based, patient-specific insulin dosing platform cleared for hospital use.

Glooko has won FDA clearance for EndoTool IV Cloud, a cloud-based patient-specific insulin dosing platform that supports individualized insulin dosing for hospitalized patients requiring intravenous insulin therapy.

Glooko announced that the FDA granted 510(k) clearance for its EndoTool IV Cloud, a cloud-based, patient-specific insulin dosing platform.

The US FDA cleared the EndoTool IV Cloud, a cloud-based version of parent company Glooko’s inpatient intravenous insulin dosing decision-support platform, through the 510(k) pathway.

Glooko and MyLife Diabetes Care announced that they agreed to expand their partnership centered around diabetes management products.

Data presented at the 2026 AACE Annual Meeting showed that EndoTool IV, Glooko’s inpatient glycemic management solution, achieved an impressive 98% reduction in severe hypoglycemia across a 19-hospital system compared to its historical paper protocols.

Glooko sponsored the second annual Diabetes Dash 5K Run, organized by the Dartmouth Diabetes Initiative, which raised over $8,500 for diabetes education.

At AACE 2026, Glooko presented data demonstrating that EndoTool IV achieved a 98% reduction in severe hypoglycemia across a 19-hospital health system when compared to historical paper protocols

By implementing the EndoTool predictive insulin-dosing platform, Temple Health achieved a two- to three-fold reduction in inpatient hypoglycemic events while improving patient safety and reducing clinician burden.

Per Grapatin, Vice President of Engineering at Glooko, shares how the digital health company migrated more than 100 million daily glucose readings in its diabetes management platform to Tiger Cloud to cut costs 40%, boost query speed 480x, and scale diabetes patient analytics.